A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Riepilogo della notizia
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Segui le ultime notizie di fonti affidabili con brevi riepiloghi. Apri il collegamento originale per i dettagli.